CJLC 中国肺癌杂志 Chinese Journal of Lung Cancer
pISSN 1009-3419
eISSN 1999-6187
CN 12-1395/R

Efficacy of Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural or Peritoneal Effusions

Xin ZHANG, Yi HU, Jinliang WANG, Sujie ZHANG, Haitao TAO, Sun JING, Baishou WU

摘要

Background and objective Once the malignant pleural or peritoneal effusion is developed it is difficult to control. This report presents a new method for controlling the malignant effusions.
Methods Forty-eight patients, 29 males and 19 females with an average age of 61.2 years old, who were satisfied with the study inclusion criteria, were recruited in this study. Twenty-seven and 21 patients had a malignant pleural and peritoneal effusion, respectively. After draining most of fluids, these patients received intra-cavity infusion of rAd-p53 once per week for 4 weeks, at dose of 2×1012 viral particles (VP) diluted into 200 mL of saline solution for pleural effusions, and 4×1012 VP diluted into 500 mL of saline solution for peritoneal effusions. Results Participants were followed up for a median time of 13.6 month. A total of 11 cases, 7 with pleural effusions and 4 with peritoneal effusions achieved a complete response (CR), and 20 cases (12 pleural effusions and 8 peritoneal effusions) had a partial response (PR). The overall response rate is 64.6%. Patients' quality of life, assessed by using Karnofsky performance scale (KPS) scores, was improved by an average of 26.4. The one-year of overall survival rate was 54.2% with a median survival time of 12.5 months. There were no serious side effects observed except for self-limited fever found in 79.8% of the cases. Conclusions Intra-cavity infusion of rAd-p53 is an effective and safe treatment for the patients with malignant pleural or peritoneal effusions, especially for those patients who can't tolerate the standard treatments.

DOI: 10.3779/j.issn.1009-3419.2013.03.07

全文: PDF HTML

ARTICLE TOOLS
索引源数据
如何引证项目
查找参考文献
审查政策
Email this article
(Login required)

RELATED ITEMS
Related studies
Databases
Web search
Show all

ABOUT THE AUTHORS

Xin ZHANG
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China;National Key Lab of Molecular Oncology, Cancer Institute & Hospital, CAMS, Beijing 100021, China

Yi HU
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China

Jinliang WANG
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China

Sujie ZHANG
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China

Haitao TAO
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China

Sun JING
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China

Baishou WU
Department of Oncology, the General Hospital of Chinese PLA, Beijing 100853, China